Literature DB >> 19690457

Oncogenic K-ras "addiction" and synthetic lethality.

Anurag Singh, Jeff Settleman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19690457      PMCID： PMC5707179          DOI： 10.4161/cc.8.17.9336

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  13 in total

Review 1.  The Ras superfamily at a glance.

Authors:  Krister Wennerberg; Kent L Rossman; Channing J Der
Journal:  J Cell Sci       Date:  2005-03-01       Impact factor: 5.285

2.  A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival.

Authors:  Anurag Singh; Patricia Greninger; Daniel Rhodes; Louise Koopman; Sheila Violette; Nabeel Bardeesy; Jeff Settleman
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

Review 3.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

4.  Essential role for oncogenic Ras in tumour maintenance.

Authors:  L Chin; A Tam; J Pomerantz; M Wong; J Holash; N Bardeesy; Q Shen; R O'Hagan; J Pantginis; H Zhou; J W Horner; C Cordon-Cardo; G D Yancopoulos; R A DePinho
Journal:  Nature       Date:  1999-07-29       Impact factor: 49.962

Review 5.  Genetics and biology of pancreatic ductal adenocarcinoma.

Authors:  Aram F Hezel; Alec C Kimmelman; Ben Z Stanger; Nabeel Bardeesy; Ronald A Depinho
Journal:  Genes Dev       Date:  2006-05-15       Impact factor: 11.361

6.  K-ras is an essential gene in the mouse with partial functional overlap with N-ras.

Authors:  L Johnson; D Greenbaum; K Cichowski; K Mercer; E Murphy; E Schmitt; R T Bronson; H Umanoff; W Edelmann; R Kucherlapati; T Jacks
Journal:  Genes Dev       Date:  1997-10-01       Impact factor: 11.361

Review 7.  ras oncogenes in human cancer: a review.

Authors:  J L Bos
Journal:  Cancer Res       Date:  1989-09-01       Impact factor: 12.701

Review 8.  Modelling oncogenic Ras/Raf signalling in the mouse.

Authors:  Florian A Karreth; David A Tuveson
Journal:  Curr Opin Genet Dev       Date:  2009-02-07       Impact factor: 5.578

9.  Genetic predictors of MEK dependence in non-small cell lung cancer.

Authors:  Christine A Pratilas; Aphrothiti J Hanrahan; Ensar Halilovic; Yogindra Persaud; Junichi Soh; Dhananjay Chitale; Hisayuki Shigematsu; Hiromasa Yamamoto; Ayana Sawai; Manickam Janakiraman; Barry S Taylor; William Pao; Shinichi Toyooka; Marc Ladanyi; Adi Gazdar; Neal Rosen; David B Solit
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

10.  A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.

Authors:  Ji Luo; Michael J Emanuele; Danan Li; Chad J Creighton; Michael R Schlabach; Thomas F Westbrook; Kwok-Kin Wong; Stephen J Elledge
Journal:  Cell       Date:  2009-05-29       Impact factor: 41.582
View more
  20 in total

1.  Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Authors:  Richard Marcotte; Kevin R Brown; Fernando Suarez; Azin Sayad; Konstantina Karamboulas; Paul M Krzyzanowski; Fabrice Sircoulomb; Mauricio Medrano; Yaroslav Fedyshyn; Judice L Y Koh; Dewald van Dyk; Bodhana Fedyshyn; Marianna Luhova; Glauber C Brito; Franco J Vizeacoumar; Frederick S Vizeacoumar; Alessandro Datti; Dahlia Kasimer; Alla Buzina; Patricia Mero; Christine Misquitta; Josee Normand; Maliha Haider; Troy Ketela; Jeffrey L Wrana; Robert Rottapel; Benjamin G Neel; Jason Moffat
Journal:  Cancer Discov       Date:  2011-12-29       Impact factor: 39.397

Review 2.  An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer.

Authors:  Silvia von Karstedt; Henning Walczak
Journal:  Cell Death Discov       Date:  2020-03-17

3.  Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction.

Authors:  Peter S Choi; Jan van Riggelen; Andrew J Gentles; Pavan Bachireddy; Kavya Rakhra; Stacey J Adam; Sylvia K Plevritis; Dean W Felsher
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

4.  Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival.

Authors:  David L Masica; Rachel Karchin
Journal:  Cancer Res       Date:  2011-05-09       Impact factor: 12.701

Review 5.  Molecular Pathogenesis of Pancreatic Cancer.

Authors:  T J Grant; K Hua; A Singh
Journal:  Prog Mol Biol Transl Sci       Date:  2016-10-15       Impact factor: 3.622

6.  Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism.

Authors:  Haoqiang Ying; Alec C Kimmelman; Costas A Lyssiotis; Sujun Hua; Gerald C Chu; Eliot Fletcher-Sananikone; Jason W Locasale; Jaekyoung Son; Hailei Zhang; Jonathan L Coloff; Haiyan Yan; Wei Wang; Shujuan Chen; Andrea Viale; Hongwu Zheng; Ji-hye Paik; Carol Lim; Alexander R Guimaraes; Eric S Martin; Jeffery Chang; Aram F Hezel; Samuel R Perry; Jian Hu; Boyi Gan; Yonghong Xiao; John M Asara; Ralph Weissleder; Y Alan Wang; Lynda Chin; Lewis C Cantley; Ronald A DePinho
Journal:  Cell       Date:  2012-04-27       Impact factor: 41.582

7.  Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors.

Authors:  Jennifer M Symonds; Angela M Ohm; Cristan J Carter; Lynn E Heasley; Theresa A Boyle; Wilbur A Franklin; Mary E Reyland
Journal:  Cancer Res       Date:  2011-02-18       Impact factor: 12.701

8.  Ras-mutant cancer cells display B-Raf binding to Ras that activates extracellular signal-regulated kinase and is inhibited by protein kinase A phosphorylation.

Authors:  Yanping Li; Maho Takahashi; Philip J S Stork
Journal:  J Biol Chem       Date:  2013-07-26       Impact factor: 5.157

9.  Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.

Authors:  Jae-Young Kim; Eric A Welsh; Bin Fang; Yun Bai; Fumi Kinose; Steven A Eschrich; John M Koomen; Eric B Haura
Journal:  Mol Cancer Res       Date:  2016-07-15       Impact factor: 5.852

10.  Therapeutic silencing of KRAS using systemically delivered siRNAs.

Authors:  Chad V Pecot; Sherry Y Wu; Seth Bellister; Justyna Filant; Rajesha Rupaimoole; Takeshi Hisamatsu; Rajat Bhattacharya; Anshumaan Maharaj; Salma Azam; Cristian Rodriguez-Aguayo; Archana S Nagaraja; Maria Pia Morelli; Kshipra M Gharpure; Trent A Waugh; Vianey Gonzalez-Villasana; Behrouz Zand; Heather J Dalton; Scott Kopetz; Gabriel Lopez-Berestein; Lee M Ellis; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2014-10-03       Impact factor: 6.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.